- Category: HCV Treatment
- Published on Tuesday, 12 May 2015 00:00
- Written by Keith Alcorn
Shortening direct-acting antiviral therapy to 6 weeks for easier-to-treat patients without liver cirrhosis does not greatly reduce the efficacy of hepatitis C treatment for people with HCV genotype 1 infection, according to results of a study evaluating grazoprevir, elbasvir, and sofosbuvir (Sovaldi) in short treatment courses. Moreover, for people with HCV genotype 3 but no cirrhosis, an 8-week course of treatment was only marginally less effective than a 12-week course, even though genotype 3 infection is considered harder to treat.